San Francisco, CA (UroToday.com) — Poster session begins Thursday, February 11 at 8:00AM ET
Prostate Cancer – Advanced Disease Poster Session:
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. (Abstract 48)
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide. (Abstract 84)
Advanced Prostate Cancer Trials in Progress Poster Session:
A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS188)
Urothelial Carcinoma Poster Session:
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. (Abstract 438)
NOTE – This presentation is also featured in the urothelial carcinoma clinical trials poster highlights session on Friday, February 12 at 8:00 AM ET.
Cora N. Sternberg, M.D. Clinical Director of the Englander Institute of Precision Medicine at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Sternberg’s areas of expertise:
- Bladder cancer
- Genomics
- Immunotherapy
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Urologic cancer
- Urothelial cancer
Prostate Cancer – Advanced Disease Poster Session:
The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer (Abstract 41)
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study (Abstract 46)
Advanced Prostate Cancer Trials in Progress Poster Session:
A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract TPS188)
Scott T. Tagawa, MD, MS, FACP, Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Tagawa’s areas of expertise:
- Bladder Cancer
- Immunotherapy
- Kidney Cancer
- Medical Oncology
- Prostate Cancer
- Testicular Cancer
- Thrombosis
- Urologic Cancer
Urothelial Carcinoma Poster Session:
Single-cell DNA targeted sequencing (scDNA-seq) to test therapeutic vulnerabilities in urothelial cancer (UC) patient-derived organoids (PDO). (Abstract 464)
Bishoy M. Faltas, MD, Genitourinary Oncologist at Weill Cornell Medicine and NewYork-Presbyterian, Director of Bladder Cancer Research, Englander Institute for Precision Medicine
Dr. Faltas’ areas of expertise:
- Bladder Cancer
- Cancer of Ureter
- Genomics
- Immunotherapy
- Kidney Cancer
- Prostate Cancer
- Urethral Cancer
Source: American Society of Clinical Oncology Genitourinary Cancer Symposium. (2021, February 10). Weill Cornell Medicine Experts Presenting at 2021 ASCO GU [Press release]. Retrieved from ASCO Meeting Library ASCO GU 2021
Related Content:
The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer – Cora Sternberg
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer – Cora Sternberg